Company profile MGNX
There is not enough data for MacroGenics near me to provide analysis
There is not enough data for MacroGenics near me to provide correlation calculation
There is not enough data for MacroGenics near me to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. MacroGenics stock price expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 152 | 151 -0.7% QoQ | 16 -89.4% QoQ | 70 337.5% QoQ |
| 2020 | 41 -73.0% YoY -41.4% QoQ | 43 -71.5% YoY 4.9% QoQ | 107 568.8% YoY 148.8% QoQ | 105 50.0% YoY -1.9% QoQ |
| 2021 | 67 63.4% YoY -36.2% QoQ | 20 -53.5% YoY -70.1% QoQ | 65 -39.3% YoY 225.0% QoQ | 92 -12.4% YoY 41.5% QoQ |
| 2022 | 17 -74.6% YoY -81.5% QoQ | 43 115.0% YoY 152.9% QoQ | 41 -36.9% YoY -4.7% QoQ | 128 39.1% YoY 212.2% QoQ |
| 2023 | 157 823.5% YoY 22.7% QoQ | 128 197.7% YoY -18.5% QoQ | 115 180.5% YoY -10.2% QoQ | 81 -36.7% YoY -29.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of MacroGenics stock price was 6.28 per week. The last year interest of MacroGenics stock price compared to the last 5 years has changed by 28.98%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 3.98%.
After 39 days of this quarter the interest is at 55.0. Based on that we can calculate that during remaining 52 days it will total up to 128.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 55 | 85 54.5% QoQ | 20 -76.5% QoQ | 84 320.0% QoQ |
| 2020 | 88 60.0% YoY 4.8% QoQ | 30 -64.7% YoY -65.9% QoQ | 42 110.0% YoY 40.0% QoQ | 22 -73.8% YoY -47.6% QoQ |
| 2021 | 48 -45.5% YoY 118.2% QoQ | 200 566.7% YoY 316.7% QoQ | 249 492.9% YoY 24.5% QoQ | 22 0.0% YoY -91.2% QoQ |
| 2022 | 49 2.1% YoY 122.7% QoQ | 44 -78.0% YoY -10.2% QoQ | 58 -76.7% YoY 31.8% QoQ | 52 136.4% YoY -10.3% QoQ |
| 2023 | 150 206.1% YoY 188.5% QoQ | 139 215.9% YoY -7.3% QoQ | 116 100.0% YoY -16.5% QoQ | 163 213.5% YoY 40.5% QoQ |
| 2024 | 55 -63.3% YoY -66.3% QoQ | - | - | - |
The average 5 years interest of MacroGenics careers was 6.79 per week. The last year interest of MacroGenics careers compared to the last 5 years has changed by 57.14%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 77.24%.
There is not enough data for MacroGenics pipeline to provide analysis
There is not enough data for MacroGenics pipeline to provide correlation calculation
There is not enough data for MacroGenics pipeline to provide analysis
There is not enough data for MARGENZA cancer treatment to provide analysis
There is not enough data for MARGENZA cancer treatment to provide correlation calculation
There is not enough data for MARGENZA cancer treatment to provide analysis
There is not enough data for MGC018 antibody drug conjugate to provide analysis
There is not enough data for MGC018 antibody drug conjugate to provide correlation calculation
There is not enough data for MGC018 antibody drug conjugate to provide analysis
There is not enough data for Enoblituzumab monoclonal antibody to provide analysis
There is not enough data for Enoblituzumab monoclonal antibody to provide correlation calculation
There is not enough data for Enoblituzumab monoclonal antibody to provide analysis
There is not enough data for MGD024 bispecific CD123 × CD3 DART to provide analysis
There is not enough data for MGD024 bispecific CD123 × CD3 DART to provide correlation calculation
There is not enough data for MGD024 bispecific CD123 × CD3 DART to provide analysis
There is not enough data for Lorigerlimab PD-1 and CTLA-4 antibody to provide analysis
There is not enough data for Lorigerlimab PD-1 and CTLA-4 antibody to provide correlation calculation
There is not enough data for Lorigerlimab PD-1 and CTLA-4 antibody to provide analysis
There is not enough data for Tebotelimab PD-1 and lymphocyte-activation gene 3 DART. to provide analysis
There is not enough data for Tebotelimab PD-1 and lymphocyte-activation gene 3 DART. to provide correlation calculation
There is not enough data for Tebotelimab PD-1 and lymphocyte-activation gene 3 DART. to provide analysis